In vitro activity of ozenoxacin against quinolone-susceptible and quinolone-resistant gram-positive bacteria

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 12, 2013, Pages 6389-6392

  Lopez Y ^a,b   Tato, M ^c   Espinal, P ^a   Garcia Alonso, F ^d   Gargallo Viola, D ^d   Canton R ^c   Vila, J ^a,b  

^a CENTRE FOR RESEARCH IN ENVIRONMENTAL EPIDEMIOLOGY CREAL   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c HOSPITAL RAMÓN Y CAJAL   (Spain)

^d Ferrer Grupo   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; NEMONOXACIN; OZENOXACIN; QUINOLONE;

AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; CONTROLLED STUDY; DRUG MECHANISM; ENTEROCOCCUS FAECIUM; GRAM POSITIVE BACTERIUM; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MUTATION; NONHUMAN; PRIORITY JOURNAL; SKIN INFECTION; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; TOPICAL TREATMENT;

ANTI-BACTERIAL AGENTS; FLUOROQUINOLONES; GRAM-POSITIVE BACTERIA; MICROBIAL SENSITIVITY TESTS; QUINOLONES;

EID: 84887477233     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01509-13     Document Type: Article

References (18)

1. Almer LS, Hoffrage JB, Keller EL, Flamm RK, Shortridge VD. 2004. In vitro and bactericidal activities of ABT-492, a novel fluoroquinolone, against Gram-positive and Gram-negative organisms. Antimicrob. Agents Chemother. 48:2771-2777.
2. Zhang R, Eggleston K, Rotimi V, Zeckhauser RJ. 2006. Antibiotic resistance as a global threat: evidence from China, Kuwait and the United States. Global Health 2:6. doi:10.1186/1744-8603-2-6.
3. Maina EK, Kiiyukia C, Wamae CN, Waiyaki PG, Kariuki S. 2013. Characterization of methicillin-resistant Staphylococcus aureus from skin and soft tissue infections in patients in Nairobi, Kenya. Int. J. Infect. Dis. 17:e115-9. doi:10.1016/j.ijid.2012.09.006.
4. Rice LB. 2006. Antimicrobial resistance in gram-positive bacteria. Am. J. Med. 119(6 Suppl 1):S11-S19.
5. Bhagwat SS, McGhee P, Kosowska-Shick K, Patel MV, Appelbaum PC. 2009. In vitro activity of the quinolone WCK 771 against recent U.S. hospital and community-acquired Staphylococcus aureus pathogens with various resistance types. Antimicrob. Agents Chemother. 53:811-813.
6. Saravolatz LD, Leggett J. 2003. Gatifloxacin, gemifloxacin, and moxifloxacin: the role of 3 newer fluoroquinolones. Clin. Infect. Dis. 37:1210-1215.
7. Wiles JA, Bradbury BJ, Pucci MJ. 2010. New quinolone antibiotics: a survey of the literature from 2005 to 2010. Expert Opin. Ther. Pat. 20: 1295-1319.
8. López Y, Tato M, Cantón R, Vila J. 2012. Abstr. 52nd Intersci. Conf. Antimicrob. Agents Chemother., abstr C1-682.
9. Clinical and Laboratory Standards Institute. 2012. Performance standards for antimicrobial susceptibility testing: 21st international supplement. M100-S21. Clinical and Laboratory Standards Institute, Wayne, PA.
10. Sierra JM, Marco F, Ruiz J, Jiménez de Anta MT, Vila J. 2002. Correlation between the activity of different fluoroquinolones and the presence of mechanisms of quinolone resistance in epidemiologically related and unrelated strains of methicillin-susceptible and-resistant Staphylococcus aureus. Clin. Microbiol. Infect. 8:781-790.
11. Yamada M, Yoshida J, Hatou S, Yoshida T, Minagawa Y. 2008. Mutations in the quinolone resistance determining region in Staphylococcus epidermidis recovered from conjunctiva and their association with susceptibility to various fluoroquinolones. Br. J. Ophthalmol. 92:848-851.
12. Billal DS, Fedorko DP, Yan SS, Hotomi M, Fujihara K, Nelson N, Yamanaka N. 2007. In vitro induction and selection of fluoroquinoloneresistant mutants of Streptococcus pyogenes strains with multiple emm types. J. Antimicrob. Chemother. 59:28-34.
13. Biedenbach DJ, Toleman MA, Walsh TR, Jones RN. 2006. Characterization of fluoroquinolone-resistant beta-hemolytic Streptococcus spp. isolated in North America and Europe including the first report of fluoroquinolone- resistant Streptococcus dysgalactiae subspecies equisimilis: report from the SENTRY Antimicrobial Surveillance Program (1997- 2004). Diagn. Microbiol. Infect. Dis. 55:119-127.
14. Oyamada Y, Ito H, Fujimoto K, Asada R, Niga T, Okamoto R, Inoue M, Yamagishi J. 2006. Combination of known and unknown mechanisms confers high-level resistance to fluoroquinolones in Enterococcus faecium. J. Med. Microbiol. 55(Part 6):729-736.
15. Yamakawa T, Mitsuyama J, Hayashi K. 2002. In vitro and in vivo antibacterial activity of T-3912, a novel non-fluorinated topical quinolone. J. Antimicrob. Chemother. 49:455-465.
16. Chen YH, Liu CY, Lu JJ, King CHR, Hsueh PR. 2009. In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan. J. Antimicrob. Chemother. 64:1226-1229.
17. Ki M, Srinivasan U, Oh KY, Kim MY, Shin JH, Hong HL, Dang T, Britt Z, Foxman B. 2012. Emerging fluoroquinolone resistance in Streptococcus agalactiae in South Korea. Eur. J. Clin. Microbiol. Infect. Dis. 31:3199-3205.
18. Arai K, Hirakata Y, Yano H, Kanamori H, Endo S, Hirotani A, Abe Y, Nagasawa M, Kitagawa M, Aoyagi T, Hatta M, Yamada M, Nishimaki K, Takayama Y, Yamamoto N, Kunishima H, Kaku M. 2011. Emergence of fluoroquinolone-resistant Streptococcus pyogenes in Japan by a point mutation leading to a new amino acid substitution. J. Antimicrob. Chemother. 66:494-498.